Go offline with the Player FM app!
Pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL; murine models of erythroid 5ALA synthesis disorders; targeting PKCa in diabetes and hemochromatosis
Manage episode 442094102 series 2592278
In this week's episode we’ll discuss the safety and efficacy of pirtobrutinib with or without rituximab in relapsed/refractory CLL; learn more about erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine; and discuss how targeting PKC alpha alleviates iron overload in diabetes and hemochromatosis through the inhibition of ferroportin.
Featured Articles:
- Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: Phase 1b BRUIN trial
- Murine models of erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine
- Targeting PKCα alleviates iron overload in diabetes and hemochromatosis through the inhibition of ferroportin
290 episodes
Manage episode 442094102 series 2592278
In this week's episode we’ll discuss the safety and efficacy of pirtobrutinib with or without rituximab in relapsed/refractory CLL; learn more about erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine; and discuss how targeting PKC alpha alleviates iron overload in diabetes and hemochromatosis through the inhibition of ferroportin.
Featured Articles:
- Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: Phase 1b BRUIN trial
- Murine models of erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine
- Targeting PKCα alleviates iron overload in diabetes and hemochromatosis through the inhibition of ferroportin
290 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.